These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7575993)

  • 1. On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic.
    Todd I; Bottazzo GF
    J Autoimmun; 1995 Jun; 8(3):313-22. PubMed ID: 7575993
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aberrant expression of HLA-DR antigens and autoimmune phenomenon in endocrine diseases].
    Gutiérrez C; Fernández-Cruz E
    Rev Clin Esp; 1986 Apr; 178(6):255-8. PubMed ID: 3487815
    [No Abstract]   [Full Text] [Related]  

  • 3. The HLA histocompatibility system in autoimmune states.
    Braun WE; Zachary AA
    Clin Lab Med; 1988 Jun; 8(2):351-72. PubMed ID: 3284701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen presentation in the pathogenesis of autoimmune endocrine disease.
    Weetman AP
    J Autoimmun; 1995 Jun; 8(3):305-12. PubMed ID: 7575992
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms involved in organ-specific autoimmune diseases.
    Boitard C
    Ann Med Interne (Paris); 1999 Apr; 150(3):213-20. PubMed ID: 10445093
    [No Abstract]   [Full Text] [Related]  

  • 6. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of major histocompatibility complex class II antigen on target cells in autoimmune endocrine diseases.
    Hanafusa T
    Nihon Naibunpi Gakkai Zasshi; 1988 Dec; 64(12):1228-32. PubMed ID: 2977760
    [No Abstract]   [Full Text] [Related]  

  • 8. [The HLA system class II. Its implication in auto-immune endocrine diseases].
    Saï P; Houssaint E
    Ann Endocrinol (Paris); 1989; 50(3):237-45. PubMed ID: 2510577
    [No Abstract]   [Full Text] [Related]  

  • 9. [The current concepts of the etiology and pathogenesis of autoimmune endocrinopathies].
    Luk'ianchikov VS; Kalinin AP; Luk'ianchikov VV
    Ter Arkh; 1995; 67(10):3-6. PubMed ID: 8779099
    [No Abstract]   [Full Text] [Related]  

  • 10. [Type II autoimmune polyendocrinopathy. HLA A2, A3, B5 and DR4 antigens].
    Sadoul JL; Fredenrich A; Vinti H; Pesce A; Freychet P
    Presse Med; 1986 Nov; 15(42):2117-8. PubMed ID: 2954054
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune polyglandular syndromes.
    Neufeld M; Maclaren N; Blizzard R
    Pediatr Ann; 1980 Apr; 9(4):154-62. PubMed ID: 6990358
    [No Abstract]   [Full Text] [Related]  

  • 12. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right place, right time, right peptide: DO keeps DM focused.
    Denzin LK; Fallas JL; Prendes M; Yi W
    Immunol Rev; 2005 Oct; 207():279-92. PubMed ID: 16181343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator.
    Ramsey C; Hässler S; Marits P; Kämpe O; Surh CD; Peltonen L; Winqvist O
    Eur J Immunol; 2006 Feb; 36(2):305-17. PubMed ID: 16421949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complex role of epithelial cell MHC class II antigen expression in autoimmune endocrine disease.
    Davies TF
    Autoimmunity; 1990; 8(2):87-9. PubMed ID: 2104190
    [No Abstract]   [Full Text] [Related]  

  • 17. Discordant expression of HLA class II-associated co-chaperones and HLA-DRB alleles in cultured fibroblast-like synoviocytes.
    Spurrell DR; Oldford SA; Frost T; Larsen B; Codner D; Edgecombe A; Drover S
    Hum Immunol; 2004 Dec; 65(12):1516-29. PubMed ID: 15603880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of human insulin in the context of HLA-DRB1*0406 products by T cells of insulin autoimmune syndrome patients and healthy donors.
    Ito Y; Nieda M; Uchigata Y; Nishimura M; Tokunaga K; Kuwata S; Obata F; Tadokoro K; Hirata Y; Omori Y
    J Immunol; 1993 Nov; 151(10):5770-6. PubMed ID: 8228261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic predisposition to autoimmune endocrine diseases.
    Caillat-Zucman S
    Ann Med Interne (Paris); 1999 Apr; 150(3):221-34. PubMed ID: 10445094
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.